Immunoadsorption in systemic connective tissue diseases and primary vasculitis

Therapeutic Apheresis

Volumn 1, Issue 2, 1997, Pages 117-120

  Schneider, M ^a   Gaubitz, M ^b   Perniok, A ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Connective tissue disease; Immunoadsorption; Primary vasculitis

Indexed keywords

DEXTRAN SULFATE;

CONNECTIVE TISSUE DISEASE; EDITORIAL; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; VASCULITIS;

CONNECTIVE TISSUE DISEASES; DEXTRAN SULFATE; HUMANS; IMMUNOSORBENT TECHNIQUES; VASCULITIS;

EID: 0031128945     PISSN: 10916660     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1744-9987.1997.tb00024.x     Document Type: Article

References (22)

1. Singer DRJ, Roberts D, Cohen J. Infective complications of plasma exchange: A prospective study. Arthritis Rheum 1987; 30:443-7.
2. Gaubitz M, Schmitz-Linneweber B, Perniok A, Fischer R, Schneider M. IG-immunoadsorption in SLE. First experiences. Lupus 1995;4:S113.
3. Gjörstrup P, Watt RM. Therapeutic protein A immunoadsorption. A review. Transfus Sci 1990;11:281-302.
4. Hiepe F, Schössler W, Apostoloff E, Precht K. Development of a C1q-adsorbent for the selective removal of circulating immune complexes. Biomat Artif Cells Artif Organs 1990;18: 529-34.
5. Usada M, Maeda K, Sezaki R, Shinzato T, Kawanishi A, Niwa T, Kawaguchi S, Yamawaki N, Furuta T, Inagaki K. Clinical application of newly developed absorbent resin (I-02) for regeneration of plasma from auto-immune disease patients. In: Oda T, ed. Therapeutic plasmapheresis. Stuttgart: Schattauer Verlag, 1982:105-10.
6. Lazarus HM, Cohen SB, Clegg DO, Menitove JE, Sorin SB, Hinkle S, Markenson JA, Saal S, Goodnough LT, Fleischmann RM. Selective in vivo removal of rheumatoid factor by an extracorporeal treatment device in rheumatoid arthritis patients. Transfusion 1990;31:122-8.
7. Suzuki K, Hara M, Harigai M, Ishizuka T, Hirose T, Matsuki Y, Kawaguchi Y, Kitani A, Kawagoe M, Nakamura H. Continuous removal of anti-DNA antibody, using a new extracorporeal immunoadsorption system, in patients with systemic lupus erythematosus. Arthritis Rheum 1991:34:1546-52.
8. Ikonomov V, Samtleben W, Schmidt B, Blumenstein M, Gurland HJ. Adsorption profile of commercially available adsorbens: an in vitro evaluation. Int J Artif Organs 1992;15: 312-9.
9. Kinoshita M, Aotsuka S, Funahashi T, Tani N, Yokohari R. Selective removal of anti-double-stranded DNA antibodies by immunoadsorption with dextran sulphate in a patient with systemic lupus erythematosus. Ann Rheum Dis 1989;48: 856-60.
10. Hashimoto H, Tsuda H, Kanai Y, Kobayashi S, Hirose S, Shinoura H, Yokohari R, Kinoshita M, Aotsuka S, Yamada H, Takahashi K, Yoshinoya S, Miyamoto T. Selective removal of anti-DNA and anticardiolipin antibodies by adsorbent plasmapheresis using dextran sulfate columns in patients with systemic lupus erythematosus. J Rheumatol 1990;18:545-51.
11. Tokuda M, Inoh M, Akashi Y, Seto K, Kurata N, Takahara J. Randomized open trial to elucidate the effect of immunoadsorption anti-DNA antibodies in SLE patients. Therapeutic Plasmapheresis (in press).
12. Waldendorf M, Schneider M, Lohmann J. Immunoadsorbent perfusion therapy of patients with SLE. Clin Exp Rheumatol 1987;5(S-2):208.
13. Shibuya N, Sato T, Osame M, Takegami T, Doi S, Kawanami S. Immunoadsortion therapy for myasthenia gravis. J Neurol Neurosurg Psychiatry 1994;57:578-81.
14. Gaubitz M, Schneider M. Extracorporeal therapy in systemic lupus erythematosus. J Clin Apheresis (in press).
15. Langone JJ. Protein A of Staphyloccocus aureus and related immunoglobulin receptors produced by streptococci and pneumoccoci. Adv Immunol 1982;32:157-252.
16. Esnault VLM, Testa A, Yayne DRW, Soulillou JP, Guenel J. Influence of immunoadsorption on the removal of immunoglobulin G autoantibodies in crescentic glomerulonephritis. Nephron 1992;65:180-4.
17. Palmer A, Cairns T, Dische F, Gluck G, Gjorstrup P, Parons V, Welsh K, Taubede. Treatment of rapidly progressive glomerulonephritis by extracorporeal immunoadsorption, prednisolone and cyclophosphamide. Nephrol Dial Transplant 1991;6:536-42.
18. du Moulin A, Müller-Derlich J, Bieber F, Richter WO, Frei U, Müller R, Spaethe R. Antibody-based immunoadsorption as a therapeutic means. Blood Purif 1993;11:145-9.
19. Gaubitz M, Schmitz-Linneweber B, Hartmann M, Domschke W, Schneider M. Immunoglobulinadsorption in SLE: Experiences with 10 patients. Therapeutic Plasmapheresis (in press).
20. Terman DS, Stewart I, Robinette J, Carr R, Harbeck R. Specific removal of DNA antibodies in vivo with an extracorporeal immuno-adsorbent. Clin Exp Immunol 1976;24:231-7.
21. Traeger J, Laville M, Serres PF, Cronenberger M, Thomas M, Rey MJ, Bourgeat C. A new device for specific extracorporeal immunoadsorption of anti-DNA antibodies. Ann Med Intern 1992;143:9-12.
22. McLeod B, Lewis E, Schnitzer T, Katz R, Korbet S, Neighbour A, Wong W. Therapeutic immunoadsorption of antinative DNA antibodies in SLE: Clinical studies with a device utilizing monoclonal anti-idiotypic antibody. Arthritis Rheum 1988;31:S15.